---
title: "Moleculin: Buy Rating Maintained as MIRACLE Trial Progress Offsets Dilution; McCarthy Trims Price Target After Equity Financing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296002980.md"
description: "Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin (MBRX) on August 4, citing positive progress in the MIRACLE trial for Annamycin, which showed meaningful remission rates and no cardiotoxicity. Although McCarthy lowered the price target to account for dilution from recent equity financing, he believes the raised capital extends the cash runway into early 207, allowing the company to reach pivotal unblinded data that could re-rate shares. Roth MKM also maintained a Buy rating with a $31.00 price target."
datetime: "2026-08-15T14:05:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296002980.md)
  - [en](https://longbridge.com/en/news/296002980.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296002980.md)
generator: "portal-rs"
---

# Moleculin: Buy Rating Maintained as MIRACLE Trial Progress Offsets Dilution; McCarthy Trims Price Target After Equity Financing

Maxim Group analyst Jason McCarthy has maintained their bullish stance on MBRX stock, giving a Buy rating on August 4.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Jason McCarthy has given his Buy rating due to a combination of factors related to Moleculin’s clinical progress and financial position. He views the ongoing MIRACLE trial of Annamycin in relapsed/refractory AML as on track, with blinded interim results showing meaningful remission rates and an encouraging safety profile, particularly the lack of cardiotoxicity.

At the same time, McCarthy acknowledges the dilutive impact of the recent equity financing and accordingly reduces his price target, yet he believes the capital raise provides sufficient cash runway into early 2027. In his assessment, this extended runway should allow Moleculin to reach the pivotal unblinded data from the 90-patient cohort, which, if positive, could materially re-rate the shares and justify a Buy recommendation despite near-term dilution.

McCarthy covers the Healthcare sector, focusing on stocks such as AIM ImmunoTech, Medicinova, and Inmune Bio. According to TipRanks, McCarthy has an average return of -12.0% and a 31.00% success rate on recommended stocks. 

In another report released on August 4, Roth MKM also maintained a Buy rating on the stock with a $31.00 price target.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [INMB.US](https://longbridge.com/en/quote/INMB.US.md)
- [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md)
- [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [Moleculin Biotech announces annual shareholder meeting](https://longbridge.com/en/news/296828733.md)
- [Moleculin Biotech reports interim MIRACLE trial data showing higher remission rates in relapsed/refractory AML](https://longbridge.com/en/news/295935232.md)
- [ExpreS2ion says ES2B-C001 Phase I trial shows anti-HER2 antibody response in 12 of 13 patients, no dose-limiting toxicities](https://longbridge.com/en/news/296452642.md)
- [How Investors Are Reacting To Medtronic (MDT) Cardiac Ablation Surge And Near-Dividend-King Milestone](https://longbridge.com/en/news/296452586.md)
- [Realheart targets February 2028 readiness for first-in-human implant of total artificial heart](https://longbridge.com/en/news/296444895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**